Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. more
Time Frame | ALNY | Sector | S&P500 |
---|---|---|---|
1-Week Return | -1.35% | -0.33% | -1.49% |
1-Month Return | -3.08% | -4.57% | -0.37% |
3-Month Return | -10.24% | -9.96% | 3.89% |
6-Month Return | 9.13% | -5.67% | 9.34% |
1-Year Return | 27.22% | 2.53% | 25.19% |
3-Year Return | 50.98% | -1.43% | 24.7% |
5-Year Return | 106.69% | 34.73% | 85.39% |
10-Year Return | 160.1% | 102.14% | 187.19% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 219.75M | 492.85M | 844.29M | 1.04B | 1.83B | [{"date":"2019-12-31","value":12.02,"profit":true},{"date":"2020-12-31","value":26.96,"profit":true},{"date":"2021-12-31","value":46.18,"profit":true},{"date":"2022-12-31","value":56.74,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Cost of Revenue | 25.06M | 78.05M | 140.14M | 168.82M | 310.41M | [{"date":"2019-12-31","value":8.07,"profit":true},{"date":"2020-12-31","value":25.15,"profit":true},{"date":"2021-12-31","value":45.15,"profit":true},{"date":"2022-12-31","value":54.39,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | 194.69M | 414.80M | 704.14M | 868.60M | 1.52B | [{"date":"2019-12-31","value":12.83,"profit":true},{"date":"2020-12-31","value":27.33,"profit":true},{"date":"2021-12-31","value":46.39,"profit":true},{"date":"2022-12-31","value":57.22,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Margin | 88.60% | 84.16% | 83.40% | 83.73% | 83.02% | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":95,"profit":true},{"date":"2021-12-31","value":94.14,"profit":true},{"date":"2022-12-31","value":94.51,"profit":true},{"date":"2023-12-31","value":93.71,"profit":true}] |
Operating Expenses | 1.13B | 1.24B | 1.41B | 1.65B | 1.80B | [{"date":"2019-12-31","value":63,"profit":true},{"date":"2020-12-31","value":69.07,"profit":true},{"date":"2021-12-31","value":78.49,"profit":true},{"date":"2022-12-31","value":91.87,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (939.43M) | (828.44M) | (708.65M) | (785.07M) | (282.18M) | [{"date":"2019-12-31","value":-93943100000,"profit":false},{"date":"2020-12-31","value":-82843800000,"profit":false},{"date":"2021-12-31","value":-70865200000,"profit":false},{"date":"2022-12-31","value":-78507200000,"profit":false},{"date":"2023-12-31","value":-28217500000,"profit":false}] |
Total Non-Operating Income/Expense | 87.63M | (99.85M) | (284.93M) | (473.08M) | (177.00M) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-113.95,"profit":false},{"date":"2021-12-31","value":-325.17,"profit":false},{"date":"2022-12-31","value":-539.89,"profit":false},{"date":"2023-12-31","value":-202,"profit":false}] |
Pre-Tax Income | (885.25M) | (855.60M) | (852.14M) | (1.13B) | (433.52M) | [{"date":"2019-12-31","value":-88525300000,"profit":false},{"date":"2020-12-31","value":-85560000000,"profit":false},{"date":"2021-12-31","value":-85214400000,"profit":false},{"date":"2022-12-31","value":-112699300000,"profit":false},{"date":"2023-12-31","value":-43351700000,"profit":false}] |
Income Taxes | 863.00K | 2.68M | 680.00K | 4.16M | 6.72M | [{"date":"2019-12-31","value":12.83,"profit":true},{"date":"2020-12-31","value":39.87,"profit":true},{"date":"2021-12-31","value":10.11,"profit":true},{"date":"2022-12-31","value":61.9,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Income After Taxes | (886.12M) | (858.28M) | (852.82M) | (1.13B) | (440.24M) | [{"date":"2019-12-31","value":-88611600000,"profit":false},{"date":"2020-12-31","value":-85828100000,"profit":false},{"date":"2021-12-31","value":-85282400000,"profit":false},{"date":"2022-12-31","value":-113115600000,"profit":false},{"date":"2023-12-31","value":-44024200000,"profit":false}] |
Income From Continuous Operations | (886.12M) | (858.28M) | (852.82M) | (1.13B) | (440.24M) | [{"date":"2019-12-31","value":-88611600000,"profit":false},{"date":"2020-12-31","value":-85828100000,"profit":false},{"date":"2021-12-31","value":-85282400000,"profit":false},{"date":"2022-12-31","value":-113115600000,"profit":false},{"date":"2023-12-31","value":-44024200000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (886.12M) | (858.28M) | (852.82M) | (1.13B) | (440.24M) | [{"date":"2019-12-31","value":-88611600000,"profit":false},{"date":"2020-12-31","value":-85828100000,"profit":false},{"date":"2021-12-31","value":-85282400000,"profit":false},{"date":"2022-12-31","value":-113115600000,"profit":false},{"date":"2023-12-31","value":-44024200000,"profit":false}] |
EPS (Diluted) | (8.15) | (7.66) | (7.12) | (8.66) | (3.56) | [{"date":"2019-12-31","value":-815,"profit":false},{"date":"2020-12-31","value":-766,"profit":false},{"date":"2021-12-31","value":-712,"profit":false},{"date":"2022-12-31","value":-866,"profit":false},{"date":"2023-12-31","value":-356,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
ALNY | |
---|---|
Cash Ratio | 2.27 |
Current Ratio | 2.75 |
Quick Ratio | 2.69 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
ALNY | |
---|---|
ROA (LTM) | -2.92% |
ROE (LTM) | -1500.66% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
ALNY | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.99 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.01 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
ALNY | |
---|---|
Trailing PE | NM |
Forward PE | 909.09 |
P/S (TTM) | 14.98 |
P/B | 965.78 |
Price/FCF | 794 |
EV/R | 14.21 |
EV/Ebitda | 204.85 |
PEG | NM |
Alnylam Pharmaceuticals Inc (ALNY) share price today is $243.25
Yes, Indians can buy shares of Alnylam Pharmaceuticals Inc (ALNY) on Vested. To buy Alnylam Pharmaceuticals Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ALNY stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Alnylam Pharmaceuticals Inc (ALNY) via the Vested app. You can start investing in Alnylam Pharmaceuticals Inc (ALNY) with a minimum investment of $1.
You can invest in shares of Alnylam Pharmaceuticals Inc (ALNY) via Vested in three simple steps:
The 52-week high price of Alnylam Pharmaceuticals Inc (ALNY) is $304.39. The 52-week low price of Alnylam Pharmaceuticals Inc (ALNY) is $141.98.
The price-to-earnings (P/E) ratio of Alnylam Pharmaceuticals Inc (ALNY) is
The price-to-book (P/B) ratio of Alnylam Pharmaceuticals Inc (ALNY) is 965.78
The dividend yield of Alnylam Pharmaceuticals Inc (ALNY) is 0.00%
The market capitalization of Alnylam Pharmaceuticals Inc (ALNY) is $31.37B
The stock symbol (or ticker) of Alnylam Pharmaceuticals Inc is ALNY